Notice of Preliminary Results

RNS Number : 8890I

Allergy Therapeutics PLC

05 September 2016

 



5 September 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of Preliminary Results

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its preliminary results for the twelve-month period ended 30 June 2016 on Monday 26 September 2016.

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a presentation and conference call for analysts on the day of results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

NOREAFNLEDKKEAF